Associations of Monocyte Count and Other Immune Cell Types with Interstitial Lung Abnormalities

Kim, John S.; Axelsson, Gísli Thor; Moll, Matthew; Anderson, Michaela R.; Bernstein, Elana J.; Putman, Rachel K.; Hida, Tomoyuki; Hatabu, Hiroto; Hoffman, Eric A.; Raghu, Ganesh; Kawut, Steven M.; Doyle, Margaret F.; Tracy, Russell P.; Launer, Lenore J.; Manichaikul, Ani; Rich, Stephen S.; Lederer, David J.; Gudnason, Vilmundur; Hobbs, Brian D.; Cho, Michael H.; Hunninghake, Gary M.; Garcia, Christine Kim; Guðmundsson, Gunnar; Barr, R. Graham; Podolanczuk, Anna J.

doi:10.1164/rccm.202108-1967oc

Cited by 14 publications

(11 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Clinicians should be aware that eventually, a majority of patients with fibrotic ILDs will experience disease progression, sometimes several years after the diagnosis; therefore, long-term follow-up is warranted. Compared with those with connective tissue disease-associated ILD, patients with fibrotic hypersensitivity pneumonitis and those with non-IPF idiopathic interstitial pneumonia more frequently experienced disease progression and had a greater risk of death after satisfying PPF criteria, paralleling previous studies (13)(14)(15)(16). Thus, heterogeneity in disease course remains among ILD subtypes even after satisfying PPF criteria.…”

Section: Criteria For Progressive Pulmonary Fibrosis: Getting the Hor...supporting

confidence: 73%

“…Since then, studies have assessed the prevalence of PPF among non-IPF fibrotic ILDs and confirmed the impact of disease progression on subsequent mortality (13)(14)(15)(16). Progression was generally defined using original or modified INBUILD criteria (11,17).…”

Section: Criteria For Progressive Pulmonary Fibrosis: Getting the Hor...mentioning

confidence: 99%

“…The question remains, though, whether people with ILAs can be discharged from follow-up if lung function is normal and there are no signs of definite fibrosis on CT. Although several studies have identified blood biomarkers and genetic polymorphisms related to the presence of ILAs, limited data exist on biomarkers predictive of ILA progression (15,16). It would be interesting to link the proposed suspected ILD classification with biomarkers and genetic data in COPDGene.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Risk Stratifying Interstitial Lung Abnormalities to Guide Early Diagnosis of Interstitial Lung Diseases

Wijsenbeek

Brusselle

2023

Am J Respir Crit Care Med

View full text Add to dashboard Cite

Section: Criteria For Progressive Pulmonary Fibrosis: Getting the Hor...supporting

confidence: 73%

Section: Criteria For Progressive Pulmonary Fibrosis: Getting the Hor...mentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Risk Stratifying Interstitial Lung Abnormalities to Guide Early Diagnosis of Interstitial Lung Diseases

Wijsenbeek

Brusselle

2023

Am J Respir Crit Care Med

View full text Add to dashboard Cite

“…Several studies of specific biomarkers have been performed in individuals with ILA. Serum levels of galectin-3, sICAM-1, blood monocytes, and a number of aging-related proteins (including GDF15, TNFR, CRP, and IL-6) have been associated with an increased likelihood of ILA ( 10 – 13 ). Increased levels of matrix metalloprotease-7 have been shown to predict progression of ILA ( 14 ).…”

mentioning

confidence: 99%

Biomarkers for Interstitial Lung Abnormalities: A Stepping-stone Toward Idiopathic Pulmonary Fibrosis Prevention?

Maher

2022

Am J Respir Crit Care Med

View full text Add to dashboard Cite

“…While the details of recruitment and involvement of these cells are outside scope of this review, these processes can take place through both soluble mediators ( Huang et al, 2020 ; van Geffen et al, 2021 ) and mechanical factors ( Du et al, 2022 ). Higher counts of monocytes in blood were associated with faster disease progression in interstitial lung diseases ( Kim et al, 2022 ). In mice, monocytes arriving in fibrotic lung tissue transform to macrophages to repopulate lung tissue and remain in the tissue with higher profibrotic activity compared to tissue-resident macrophages ( Misharin et al, 2017 ).…”

Section: A Hazardous Highway: Altered Ecm In Lung Diseases and Effect...mentioning

confidence: 99%

Highway to heal: Influence of altered extracellular matrix on infiltrating immune cells during acute and chronic lung diseases

Joglekar

Nizamoglu²,

Fan³

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Environmental insults including respiratory infections, in combination with genetic predisposition, may lead to lung diseases such as chronic obstructive pulmonary disease, lung fibrosis, asthma, and acute respiratory distress syndrome. Common characteristics of these diseases are infiltration and activation of inflammatory cells and abnormal extracellular matrix (ECM) turnover, leading to tissue damage and impairments in lung function. The ECM provides three-dimensional (3D) architectural support to the lung and crucial biochemical and biophysical cues to the cells, directing cellular processes. As immune cells travel to reach any site of injury, they encounter the composition and various mechanical features of the ECM. Emerging evidence demonstrates the crucial role played by the local environment in recruiting immune cells and their function in lung diseases. Moreover, recent developments in the field have elucidated considerable differences in responses of immune cells in two-dimensional versus 3D modeling systems. Examining the effect of individual parameters of the ECM to study their effect independently and collectively in a 3D microenvironment will help in better understanding disease pathobiology. In this article, we discuss the importance of investigating cellular migration and recent advances in this field. Moreover, we summarize changes in the ECM in lung diseases and the potential impacts on infiltrating immune cell migration in these diseases. There has been compelling progress in this field that encourages further developments, such as advanced in vitro 3D modeling using native ECM-based models, patient-derived materials, and bioprinting. We conclude with an overview of these state-of-the-art methodologies, followed by a discussion on developing novel and innovative models and the practical challenges envisaged in implementing and utilizing these systems.

show abstract

Associations of Monocyte Count and Other Immune Cell Types with Interstitial Lung Abnormalities

Cited by 14 publications

References 43 publications

Risk Stratifying Interstitial Lung Abnormalities to Guide Early Diagnosis of Interstitial Lung Diseases

Risk Stratifying Interstitial Lung Abnormalities to Guide Early Diagnosis of Interstitial Lung Diseases

Biomarkers for Interstitial Lung Abnormalities: A Stepping-stone Toward Idiopathic Pulmonary Fibrosis Prevention?

Highway to heal: Influence of altered extracellular matrix on infiltrating immune cells during acute and chronic lung diseases

Contact Info

Product

Resources

About